10-Q: Oramed Pharmaceuticals Reports Q2 2024 Results, Driven by Financial Gains and Strategic Review

Oramed Pharmaceuticals reported a net income of $10.7 million for the second quarter of 2024, primarily driven by financial income from its investment in Scilex Holding Company, while research and development expenses decreased.

Summary

• Oramed Pharmaceuticals reported a net income of $10.7 million for the six months ended June 30, 2024, a significant turnaround from a net loss of $4.9 million in the same period last year.
• The company's financial performance was primarily boosted by a net financial income of $19.3 million, largely due to the revaluation of investments in Scilex Holding Company.
• Research and development expenses decreased by 58% to $2.6 million for the six months ended June 30, 2024, compared to $6.2 million in the same period of 2023, due to the termination of Phase 3 trials.
• General and administrative expenses also saw a decrease of 6% to $3.5 million for the six months ended June 30, 2024, compared to $3.7 million for the same period in 2023.
• The company's cash and cash equivalents increased significantly to $84.8 million as of June 30, 2024, compared to $9.1 million at the end of 2023.
• Oramed has a working capital surplus of $149.5 million and an accumulated loss of $146.8 million as of June 30, 2024.
• The company is currently undergoing a strategic review process to enhance value for stockholders.
• Oramed has entered into a joint venture agreement with HTIT Biotech to develop and commercialize oral insulin and other products, with HTIT contributing $70 million and Oramed contributing $20 million in cash and shares, plus intellectual property.
• As of June 30, 2024, Scilex has repaid $40 million of the $101.9 million principal amount due under the Senior Secured Promissory Note.

Sentiment

Score: 7

Explanation: The document shows a positive financial turnaround and strategic moves, but there are still risks and uncertainties related to product development and external financing. The sentiment is cautiously optimistic.

Positives

• The company has achieved a significant turnaround in profitability, moving from a loss to a substantial net income.
• The increase in cash and cash equivalents provides a strong financial position for future operations and strategic initiatives.
• The joint venture with HTIT Biotech provides a potential pathway for future growth and commercialization of Oramed's technology.
• The repayment of $40 million by Scilex reduces the risk associated with the promissory note.
• The company has reduced operating expenses, particularly in research and development, which is a positive sign for cost management.

Negatives

• The company has not generated significant revenues from its operations.
• The termination of the Phase 3 trials for oral insulin is a setback for the company's core product development.
• The company is still reliant on external financing to fund its operations.
• The joint venture agreement is subject to additional agreements, and there is no guarantee that these will be completed.

Risks

• The company's future success is dependent on the successful development and commercialization of its products.
• The company is exposed to the risk of potential litigation.
• The company's ability to recover the proceeds and/or collateral under the Note from Scilex is not guaranteed.
• The fluctuating market price and liquidity of Scilex's common stock underlying the warrants held by Oramed could impact the value of the investment.
• The ongoing conflict in Israel could potentially impact the company's operations.
• There is no assurance that the parties will complete and sign the additional agreements related to the joint venture.

Future Outlook

The company plans to evaluate potential strategic opportunities and is working on a protocol for a new Phase 3 clinical trial. They believe they can maintain current activities for at least the next 12 months based on current cash resources.

Management Comments

• The company is examining its existing pipeline and has commenced an evaluation process of potential strategic opportunities, with the goal of enhancing value for our stockholders.
• Based on our current cash resources and commitments, we believe we will be able to maintain our current planned activities and the corresponding level of expenditures for at least the next 12 months.

Industry Context

The biotechnology industry is characterized by high research and development costs and the need for significant capital investment. Oramed's focus on oral drug delivery technology is a niche area with potential for significant market disruption if successful. The company's strategic review and joint venture agreement are indicative of a shift towards a more commercialization-focused approach.

Comparison to Industry Standards

• Oramed's significant increase in cash and cash equivalents is a positive sign compared to many biotech companies that often struggle with funding.
• The reduction in R&D expenses is a deviation from the norm for biotech companies, which typically invest heavily in R&D. This is due to the termination of the Phase 3 trials.
• The joint venture with HTIT Biotech is a strategic move that could provide Oramed with access to manufacturing capabilities and technologies, which is a common strategy for biotech companies.
• The company's reliance on external financing is typical for biotech companies in the development stage.
• The company's investment in Scilex and the subsequent financial gains are not typical for biotech companies, which usually focus on their core product development.

Management Changes

Related Party Transactions

• The company has consulting agreements with KNRY Ltd., owned by the Chief Scientific Officer, and Shnida Ltd., owned by the President and Chief Executive Officer.

Stakeholder Impact

• Shareholders may benefit from the improved financial performance and strategic initiatives.
• Employees may be impacted by the strategic review and potential changes in operations.
• Customers and partners may be affected by the company's product development and commercialization plans.
• Creditors may be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to evaluate potential strategic opportunities.
• The company will work on a protocol for a new Phase 3 clinical trial.
• The company will work towards completing the additional agreements related to the joint venture with HTIT Biotech.

Key Dates

Keywords

Oramed Pharmaceuticals, Oral Insulin, Joint Venture, Scilex Holding Company, Financial Results, Strategic Review, Biotechnology, Drug Delivery, Phase 3 Trials, Net Income, Research and Development, HTIT Biotech